Evidence map›Paper›PMID 41815506›Full record

ArticleJTO clinical and research reports2026

MET-Driven Resistance to Sotorasib in KRAS G12C-Mutant NSCLC and Response to Combined KRAS and MET Inhibition.

Richard Riedel, Lea Ruge, Malte Verheyen, Felix John, Heather Scharpenseel, Lucia Nogova, Sebastian Michels, Rieke N Fischer, Anna Eisert, Carolin Jakob and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JTO clinical and research reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Richard RiedelDepartment I of Internal Medicine, University Hospital Cologne, Cologne, Germany.
Lea RugeDepartment I of Internal Medicine, University Hospital Cologne, Cologne, Germany.
Malte VerheyenDepartment I of Internal Medicine, University Hospital Cologne, Cologne, Germany.
Felix JohnDepartment I of Internal Medicine, University Hospital Cologne, Cologne, Germany.
Heather ScharpenseelDepartment I of Internal Medicine, University Hospital Cologne, Cologne, Germany.
Lucia NogovaDepartment I of Internal Medicine, University Hospital Cologne, Cologne, Germany.
Sebastian MichelsDepartment I of Internal Medicine, University Hospital Cologne, Cologne, Germany.
Rieke N FischerDepartment I of Internal Medicine, University Hospital Cologne, Cologne, Germany.
Anna EisertDepartment I of Internal Medicine, University Hospital Cologne, Cologne, Germany.
Carolin JakobDepartment I of Internal Medicine, University Hospital Cologne, Cologne, Germany.
Emanuel NiesenDepartment I of Internal Medicine, University Hospital Cologne, Cologne, Germany.
Jana FassunkeCenter for Integrated Oncology, University Hospital Cologne, Cologne, Germany.
Janna Siemanowski-HrachCenter for Integrated Oncology, University Hospital Cologne, Cologne, Germany.
Carina HeydtCenter for Integrated Oncology, University Hospital Cologne, Cologne, Germany.
Anne BunckCenter for Integrated Oncology, University Hospital Cologne, Cologne, Germany.
Udo SieboltsCenter for Integrated Oncology, University Hospital Cologne, Cologne, Germany.
Sabine Merkelbach-BruseCenter for Integrated Oncology, University Hospital Cologne, Cologne, Germany.
Reinhard BuettnerCenter for Integrated Oncology, University Hospital Cologne, Cologne, Germany.
Jürgen WolfDepartment I of Internal Medicine, University Hospital Cologne, Cologne, Germany.
Matthias SchefflerDepartment I of Internal Medicine, University Hospital Cologne, Cologne, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Methods: We conducted a retrospective case series of patients with Results: Nine patients with paired pre and posttreatment biopsies were identified. High-level Conclusion: This study provides real-world evidence that

Indexed as

KRAS G12CMET amplificationNSCLCSotorasibTyrosine kinase inhibitor resistance

Identifiers

PMID41815506
PMCPMC12971985

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.